U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C15H8ClF6NO2
Molecular Weight 383.673
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of IMD-0354

SMILES

OC1=CC=C(Cl)C=C1C(=O)NC2=CC(=CC(=C2)C(F)(F)F)C(F)(F)F

InChI

InChIKey=CHILCFMQWMQVAL-UHFFFAOYSA-N
InChI=1S/C15H8ClF6NO2/c16-9-1-2-12(24)11(6-9)13(25)23-10-4-7(14(17,18)19)3-8(5-10)15(20,21)22/h1-6,24H,(H,23,25)

HIDE SMILES / InChI

Description

IMD-0354 is an inhibitor of IκB kinase-β (IKKβ) that blocks NF-κB nuclear translocation. Attenuates myocardial ischemia/reperfusion injury by decreasing expression of adhesion molecules ICAM-1 and P-selectin and inhibiting cytokine and chemokine production in cardiomyocytes. Induces G0/G1 cell cycle arrest and apoptosis in HMC-1 and breast cancer cells. IMD-0354 had been in phase I clinical trials for the treatment of atopic dermatitis.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
250.0 nM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown
Preventing
Unknown
Primary
Unknown
Primary
Unknown
Primary
Unknown

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer


Drug as perpetrator​

PubMed

Sample Use Guides

In Vivo Use Guide
1, 5, or 10 mg/kg intraperitoneal injection in a single bolus 5 min before the start of reperfusion.
Route of Administration: Other
In Vitro Use Guide
IMD-0354 (0.1-1 uM) caused a significant reduction of both IL-1β (−77%) and MCP-1 (−76%) production in a concentration-dependent manner compared with vehicle-treated cells.